mRNA Translation Modulators Pipeline

Our high scale screening platform identifies compounds that modulate mRNA biology. Our mRNA AI image analysis then rapidly elucidates their mechanism of action.

With this unique approach we were able to develop a broad pipeline of small molecule mRNA drugs, advancing 18 discovery programs across therapeutic areas at unparalleled speed and success rate.

Anima wholly owned pipeline programs are in Fibrosis (tissue selective Collagen I translation inhibitors, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc translation inhibitors and mutation independent mKras translation inhibitors), and Neuroscience (Tau - Alzheimer’s disease and Pain - Nav1.7 translation inhibitors) with additional programs in Repeat Associated Diseases. In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our large scale collaborations with Lilly and Takeda Pharmaceuticals.

Indication Target
Discovery
Optimization
IND enabling
Anima owned
Fibrosis
Lung Fibrosis 1
Collagen-1 2
3
Other Fibrotic 4
Oncology
c-Myc tumors c-Myc 5
6
7
mKRAS tumors mKRAS 8
Neuroscience
Alzheimer TAU 9
10
Repeat diseases Undisclosed 11
Pain Nav 1.7 12
Undisclosed 13
Partnered
Huntington mHTT 14
Undisclosed takeda logo lilly logo 15
Undisclosed 16
Undisclosed 17
Undisclosed 18
Anima owned
Partnered
Area Indication mRNA modulation Target
Discovery
Optimization
IND enabling
Fibrosis Lung Fibrosis 1
Collagen-1 2
3
Other Fibrotic 4
Oncology c-Myc tumors c-Myc 5
6
7
mKRAS tumors mKRAS 8
Neuroscience Alzheimer TAU 9
10
Repeat diseases Undisclosed 11
Pain Nav 1.7 12
Undisclosed 13
Undisclosed takeda logo lilly logo 14
Huntington mHTT 15
Undisclosed 16
Undisclosed 17
Undisclosed 18